BioInformant

Your Global Leader in Stem Cell Market Research

Home » Axiogenesis » Page 2

What is the Most Predictive Cardiac Cell Model? FDA Publication Confirms COR.4U By Axiogenesis

By Leave a Comment

Two recent peer-reviewed publications underline the predictive value of Axiogenesis Cor.4U iPSC-derived cardiomyocytes (iPSC-CMs).

There was a publication earlier this year by Astra Zeneca researchers that resulted in a somewhat negative perception (mostly by iPS cell skeptics) of iPSC-derived cells. The predictive value of iPSCs was questioned, with the abstract stating, “iCell® cardiomyocytes have limited value as an integrated QT/TdP assay, highlighting the urgent need for improved experimental alternatives that may offer an accurate integrated cardiomyocyte safety model for supporting the development of new drugs without QT/TdP effects.” [Read more…]

Axiogenesis and Metrion Biosciences to Develop Human iPSC-derived Cardiomyocytes and Neurons

By Leave a Comment

Axiogenesis AG

Axiogenesis announced today that it will be collaborating with Metrion Biosciences to validate, optimise and commercialise iPSC-derived cell based assays to facilitate drug discovery and more accurately predict cardiac arrhythmia and neuronal risk. Metrion Biosciences a UK-based contract research organization (CRO) that is best known as an ion channel specialist.

Metrion BiosciencesThrough this strategic partnership, Axiogenesis continues to strengthen its position within the iPS cell marketplace as a leading provider of cell-based solutions to facilitating drug discovery, safety, and toxicology applications. To learn more, see the full press release, included below with permission from Axiogenesis.

Axiogenesis is a fascinating company specializing in the development of induced pluripotent stem cells (iPSCs) and tissue types. It is the second largest iPSC company in the world after Cellular Dynamics International (CDI), in Madison, Wisconsin.

Axiogenesis was also the first European company to license and adopt Yamanaka’s iPSC technology in 2010. The company now specializes in human induced pluripotent stem cell (hiPSC) products, including in vitro models of healthy and diseased cell types and tissues.

Top 10 iPSC Talks from Axiogenesis’ American User Symposium

By Leave a Comment

Axiogenesis hosted an American user symposium titled, “iPSC Derived Cells & Assays Come of Age.” Held in Boston, Massachusetts (June 13, 2016), the symposium explored how experts in the pharmaceutical industry and academia use Axiogenesis’ cells and assays within drug discovery, safety/toxicology screening, and bioengineering applications.

It also presented current approaches to establish and define standards for these cellular models. Widely attended by representatives from the pharmaceutical sector, symposium attendees had the valuable opportunity to view case studies of iPSC-derived cells utilized in drug development decision-making and biomedical research.

To capture highlights from the event and facilitate thought-provoking conversation, below is a list of the top 10 talks from the recent Axiogenesis’ iPSC user symposium. [Read more…]

Are You Attending the Axiogenesis iPSC Applications Workshop on September 7-9, 2016?

By Leave a Comment

Axiogenesis iPSC ConferenceRecently, Axiogenesis hosted an American symposium titled, “iPSC Derived Cells & Assays Come of Age.” Held on June 13, 2016, in Boston, Massachusetts, the symposium explored the topic of establishing global standards for iPSC-derived cell products. Because the conversation is critical to a wide range of stem cell industry stakeholders, it was widely attended by representatives from across the pharmaceutical, biotechnology, and chemical sectors.

To further support this dialog within the global marketplace, Axiogenesis is hosting Human iPSC Applications Workshop in Cologne, Germany on September 7 – 9, 2016. It will be the fourth year that Axiogenesis has organized a workshop at its headquarters in Cologne.  [Read more…]

BioInformant's World-Class Clients